This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Rahim Karjoo, M.D., F.A.S.C.P. Offers Relief To The Legions Of Morgellons Patients

LOS ANGELES, Dec. 6, 2012 /PRNewswire/ --  Morgellons disease is a controversial topic. In many corners of the medical community, its very existence is dismissed as delusional ravings, though of course these declarations are usually couched in more polite terms. Nevertheless, using the word "psycho-somatic" instead of calling someone straight up crazy isn't all that much consolation to the people who are still suffering. The rise in Morgellons cases has given Dr. Rahim Karjoo renewed enthusiasm in his intensive research for a safe and effective Morgellons cure. His years of dedicated and meticulous investigation into the causality of Morgellons have borne fruit. Today, he is able to say with confidence that he has developed a treatment for people who report symptoms of Morgellons, otherwise known as "The Karjoo Phenomenon."

It seems fitting that this obscure condition, which so many have ignored for so long, should find new and deserved attention under a new name – the name of the one man who has never given up on the people who endure this terrible affliction. Dr. Karjoo's passionate pursuit of an answer for the question of Morgellons has led him to one inescapable conclusion: this is a malady that is exogenous in nature. More specifically, the culprit is silica, or silicone dioxide, pervasive now due to the increased use of cell phones, cosmetics, and other products found everywhere in modern, developed societies.

So…are you tired of being condescendingly dismissed by other "experts" who tell you it's all in your head? Are you close to giving up? Now is not the time to lose hope. Dr. Karjoo and his work represent a very real light at the end of the tunnel. Don't you owe it to yourself to give relief one last chance? The arc of medical discovery may be long, and often agonizingly slow, but it does get there eventually, and in the case of Morgellons, Dr. Karjoo has been in the vanguard of that movement all his professional life.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.89 -0.30%
FB $117.76 0.28%
GOOG $694.60 0.32%
TSLA $231.85 -0.20%
YHOO $35.96 -0.14%


Chart of I:DJI
DOW 17,712.69 -38.22 -0.22%
S&P 500 2,055.19 -8.18 -0.40%
NASDAQ 4,746.5220 -16.7020 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs